Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial
Latest Information Update: 07 May 2024
At a glance
- Drugs Ibrutinib (Primary) ; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Melphalan; Prednisone; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms TRIANGLE
- 07 May 2024 Results assessing whether Adding ibrutinib to first-line treatment resulted in superior efficacy in younger mantle cell lymphoma patients with increased toxicity when given after ASCT, published in the Lancet
- 13 Dec 2022 Results of an analysis of genotyping and minimal residual disease assessment in cfDNA by euroclonality-NGS DNA capture assay using peripheral blood samples from a cohort of MCL treated patients in this trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 06 Nov 2019 Results (n=511) assessing safety and feasibility of Ibrutinib combined with R-CHOP/R-DHAP released at the 61st Annual Meeting and Exposition of the American Society of Hematology